Improving T cell therapy for solid tumors by targeting specific immune cells in lymph nodes
Improving engineered TCR-T cell therapy for solid tumors by targeting Tcf1+ stem-like reservoirs in tumor-draining lymph nodes
This study is looking at how to make special immune cells called T cells better at fighting solid tumors by learning from a type of T cell found in lymph nodes, which could help improve cancer treatments for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10997222 on NIH RePORTER |
What this research studies
This research investigates how engineered T cells can be improved for treating solid tumors by focusing on a specific type of immune cell found in tumor-draining lymph nodes. The study aims to understand the characteristics of these stem-like T cells, which can self-renew and become effective against tumors. By comparing these cells with engineered T cells, the research seeks to identify ways to enhance the persistence and functionality of T cell therapies. Patients may benefit from insights that could lead to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are considering or currently undergoing T cell therapy.
Not a fit: Patients with hematological malignancies or those who do not have solid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective T cell therapies for patients with solid tumors, improving treatment outcomes.
How similar studies have performed: Other research has shown promise in enhancing T cell therapies by targeting specific immune cell populations, indicating potential for success in this approach.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Nutt, William Samuel — Fred Hutchinson Cancer Center
- Study coordinator: Nutt, William Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.